Skip to content

Study · Observational study · 2016

9 results

Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.

Fujioka K, O'Neil PM, Davies M, Greenway F, C W Lau D, Claudius B, Skjøth TV, Bjørn Jensen C, P H Wilding J

Obesity (Silver Spring, Md.)1 Nov 2016Cited by 101 (Europe PMC)

PMID27804269 (opens in a new tab)PMCIDPMC5129670 (opens in a new tab)DOI10.1002/oby.21629 (opens in a new tab)PepBankPUB-27804269
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults without type 2 diabetes given liraglutide 3.0 mg, 77.3% were early responders and 22.7% early nonresponders.

    In plain wordsIn adults without type 2 diabetes on liraglutide 3.0 mg, most lost at least 4% of weight by week 16.

    Peptide
    Liraglutide
    Outcome
    Not applicableProportion of early responders, without type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Measurements

    Early responders
    77.3%
    without T2D
    Early nonresponders
    22.7%
    without T2D

    Source sentences

    Summary
    Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D).
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  2. 02HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes given liraglutide 3.0 mg, 62.7% were early responders and 37.3% early nonresponders.

    In plain wordsIn adults with type 2 diabetes on liraglutide 3.0 mg, most lost at least 4% of weight by week 16.

    Peptide
    Liraglutide
    Outcome
    Not applicableProportion of early responders, with type 2 diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Measurements

    Early responders
    62.7%
    with T2D
    Early nonresponders
    37.3%
    with T2D

    Source sentences

    Summary
    Proportions of ERs/ENRs to liraglutide 3.0 mg were 77.3%/22.7% (individuals without type 2 diabetes, T2D) and 62.7%/37.3% (those with T2D).
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  3. 03HumanObservational studyEfficacy outcome

    In adults without type 2 diabetes given liraglutide 3.0 mg, early responders lost more weight than early nonresponders.

    In plain wordsIn adults without type 2 diabetes on liraglutide 3.0 mg, early responders lost more weight than early nonresponders.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight loss at week 56, early responders vs nonresponders, without type 2 diabetes
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Measurements

    Mean weight loss
    10.8%
    early responders
    Mean weight loss
    3%
    early nonresponders

    Source sentences

    Summary
    Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D).
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  4. 04HumanObservational studyEfficacy outcome

    In adults with type 2 diabetes given liraglutide 3.0 mg, early responders lost more weight than early nonresponders.

    In plain wordsIn adults with type 2 diabetes on liraglutide 3.0 mg, early responders lost more weight than early nonresponders.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean weight loss at week 56, early responders vs nonresponders, with type 2 diabetes
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Measurements

    Mean weight loss
    8.5%
    early responders
    Mean weight loss
    3.1%
    early nonresponders

    Source sentences

    Summary
    Greater mean weight loss was observed in ERs versus ENRs: 10.8% versus 3.0% (without T2D) and 8.5% versus 3.1% (T2D).
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  5. 05HumanObservational studyEfficacy outcome

    With liraglutide 3.0 mg, a greater proportion of early responders than early nonresponders achieved 5% or more weight loss at week 56.

    In plain wordsOn liraglutide 3.0 mg, more early responders than early nonresponders lost at least 5% of body weight by week 56.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion achieving 5% or more weight loss at week 56
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg.
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  6. 06HumanObservational studyEfficacy outcome

    With liraglutide 3.0 mg, a greater proportion of early responders than early nonresponders achieved more than 10% weight loss at week 56.

    In plain wordsOn liraglutide 3.0 mg, more early responders than early nonresponders lost over 10% of body weight by week 56.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion achieving more than 10% weight loss at week 56
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg.
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  7. 07HumanObservational studyEfficacy outcome

    With liraglutide 3.0 mg, a greater proportion of early responders than early nonresponders achieved more than 15% weight loss at week 56.

    In plain wordsOn liraglutide 3.0 mg, more early responders than early nonresponders lost over 15% of body weight by week 56.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion achieving more than 15% weight loss at week 56
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    In both trials, greater proportions of ERs versus ENRs achieved ≥5%, >10%, and >15% weight loss at week 56 with liraglutide 3.0 mg.
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  8. 08HumanObservational studyEfficacy outcome

    With liraglutide 3.0 mg, early responders had greater improvements in cardiometabolic risk factors than early nonresponders.

    In plain wordsOn liraglutide 3.0 mg, early responders had bigger improvements in heart and metabolic risk factors than early nonresponders.

    Peptide
    Liraglutide
    Outcome
    MixedCardiometabolic risk factors
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.
  9. 09HumanObservational studyEfficacy outcome

    With liraglutide 3.0 mg, early responders had greater improvements in health-related quality of life scores than early nonresponders.

    In plain wordsOn liraglutide 3.0 mg, early responders had bigger gains in quality of life scores than early nonresponders.

    Peptide
    Liraglutide
    Outcome
    IncreaseHealth-related quality of life scores
    Study

    n: not reported in source

    Comparator
    Early nonresponders (<4% weight loss at week 16)
    Outcome group
    Exercise and physical function · Whole body
    Studied dose
    3.0 mg · 56 weeksAs given in this study (human).

    Source sentences

    Summary
    Greater improvements in cardiometabolic risk factors and health-related quality of life scores were observed in ERs versus ENRs.
    3 context sentences
    Title · context
    Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers.
    Summary · context
    Using pooled data from the SCALE Obesity and Prediabetes and SCALE Diabetes trials, weight loss of ≥4% at 16 weeks best predicted ≥5% weight loss after 56 weeks.
    Summary · context
    Weight loss and changes in cardiometabolic risk factors and health-related quality of life were evaluated in ERs (≥4% weight loss at week 16) and ENRs (<4% weight loss at week 16) completing 56 weeks' treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 2 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01272219

Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Novo Nordisk A/Sn = 3,7311 Jun 2011 to 2 Mar 2015

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 19 Jan 2018
CompletedPhase 3Results postedNCT01272232

Effect of Liraglutide on Body Weight in Overweight or Obese Subjects With Type 2 Diabetes: SCALE™ - Diabetes

Novo Nordisk A/Sn = 8461 Jun 2011 to 25 Jan 2013

Metabolism and Nutrition Disorder · Obesity

Trial pageClinicalTrials.govUpdated 29 Dec 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.